Join Growin Stock Community!

Verastem, inc.VSTM.US Overview

US StockHealthcare
(No presentation for VSTM)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

VSTM AI Insights

VSTM Overall Performance

VSTM AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

VSTM Recent Performance

-0.41%

Verastem, inc.

0.05%

Avg of Sector

-0.31%

S&P500

VSTM PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

VSTM Key Information

VSTM Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

VSTM Profile

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Price of VSTM

VSTM FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

VSTM Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.98
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
32.20
PB Ratio
16.91
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
82.02%
Net Margin
-1802.12%
Revenue Growth (YoY)
33.79%
Profit Growth (YoY)
9.73%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.98
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
32.20
PB Ratio
16.91
Price-to-FCF
-
Gross Margin
82.02%
Net Margin
-1802.12%
Revenue Growth (YoY)
33.79%
Profit Growth (YoY)
9.73%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is VSTM's latest earnings report released?

    The most recent financial report for Verastem, inc. (VSTM) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating VSTM's short-term business performance and financial health. For the latest updates on VSTM's earnings releases, visit this page regularly.

  • What is the operating profit of VSTM?

    According to the latest financial report, Verastem, inc. (VSTM) reported an Operating Profit of -40.75M with an Operating Margin of -362.5% this period, representing a decline of 9.82% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is VSTM's revenue growth?

    In the latest financial report, Verastem, inc. (VSTM) announced revenue of 11.24M, with a Year-Over-Year growth rate of 0%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does VSTM have?

    As of the end of the reporting period, Verastem, inc. (VSTM) had total debt of 89.48M, with a debt ratio of 0.51. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does VSTM have?

    At the end of the period, Verastem, inc. (VSTM) held Total Cash and Cash Equivalents of 137.71M, accounting for 0.78 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does VSTM go with three margins increasing?

    In the latest report, Verastem, inc. (VSTM) did not achieve the “three margins increasing” benchmark, with a gross margin of 82.6%%, operating margin of -362.5%%, and net margin of -876.3%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess VSTM's profit trajectory and future growth potential.

  • Is VSTM's EPS continuing to grow?

    According to the past four quarterly reports, Verastem, inc. (VSTM)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.35. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of VSTM?

    Verastem, inc. (VSTM)'s Free Cash Flow (FCF) for the period is -36.22M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 52.2% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.